Meta-analysis · people

Pramlintide: HbA1c down 0.43% vs placebo at 26 weeks with insulin

Checked against the paper Meta-analysisPublished by PepVault

The takeaway

For people with type 2 diabetes already on insulin and near their goal, adding pramlintide was linked to a further small HbA1c drop and some weight loss, without more severe low blood sugar events.

Kind
Meta-analysis
Studied in
People
Published
2003
Journal
Diabetes Obes Metab

What they tested

The team asked whether adding pramlintide to insulin lowers HbA1c and weight in people with type 2 diabetes who are close to, but not yet at, their blood sugar goals.

How the study was done

A pooled post hoc analysis of two randomized, double-blind, placebo-controlled trials, limited to insulin users with type 2 diabetes whose starting HbA1c (a long-term average of blood sugar) was between 7.0 and 8.5%. In this group, 80 people got placebo (a dummy shot) plus insulin and 86 got pramlintide at 120 micro g twice daily plus insulin, followed for 26 weeks.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking pramlintide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

Both groups started with an average HbA1c of 8.0%. At week 26, the pramlintide arm's HbA1c was 0.43% lower and its weight 2.0 kg lower than the placebo arm's, and both differences were statistically significant (p < 0.001). Severe low blood sugar events did not rise with pramlintide: 0.13 events per patient year versus 0.19 with placebo.

What it doesn’t show

This was a post hoc look at a subset of patients from two earlier trials, chosen after the trials were done rather than planned in advance. It lasted 26 weeks and covered only people with type 2 diabetes already on insulin.

The paper

Hollander et al. Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets. Diabetes Obes Metab. 2003.

The compound

More studies on Pramlintide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking pramlintide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo